



**Consumer Product Safety Improvement Act
General Certificate of Conformity**

As required by the Consumer Product Safety Improvement Act, the following certifies the product referenced meets all applicable testing standards.

Alkermes Drug Product:
LYBALVI® (olanzapine and samidorphan) tablets

Alkermes NDC Numbers:
7-count bottle, 20 mg/10 mg tablet, 65757-654-40
7-count bottle, 20 mg/10 mg tablet, 65757-654-41 (Samples)
30-count bottle, 20 mg/10 mg tablet, 65757-654-42
90-count bottle, 20 mg/10 mg tablet, 65757-654-44

Consumer Product Safety regulations to which the above-referenced product is being certified: Child-resistant packaging requirements under the Poison Prevention Packaging Act. The applicable CPSC regulations are codified at 16 CFR Parts 1700 and 1701.

Drug Product Package Packaging Testing Per Drug Plastics & Glass Co., Inc.:
-24 mm SecurRx® Child-Resistant Closure, Test Number DPG14-05C
-33 mm SecurRx® Child-Resistant Closure, Test Number DPG11-12C & DPGRQ0006507

Date of testing: 13 May 2014 to 06 Jun 2014 (24 mm SecurRx® CRC)
Date of testing: 03 Nov 2011 to 18 Nov 2011 (33 mm SecurRx® CRC)

Third party testing laboratory and location of testing:

Bird Dog Marketing Group, LLC
3125 Nolt Road, Lancaster, PA 17601, USA
1-717-615-9022

Place of manufacture and contact information for the individual maintaining test result records:

Director, Quality Assurance
Alkermes, Inc.
265 Olinger Circle, Wilmington, OH 45177
1-937-382-5642
QA.CPSIA@alkermes.com

Date when this product was manufactured:

Alkermes products are marked with a unique lot number which can be used to identify the date of manufacturing by contacting the Director, Quality Assurance.

U.S. Manufacturer of product:

Alkermes, Inc.
852 Winter Street
Waltham, MA 02451-1420
1-937-382-5642



©2021 Alkermes, Inc. All rights reserved.

ALKERMES® is a registered trademark of Alkermes, Inc. and

LYBALVI® is a registered trademark of Alkermes Pharma Ireland Limited, used by Alkermes, Inc., under license.